RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...
Sirolimus albumin-bound is under clinical development by Aadi Bioscience and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% ...
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with ...
Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...
1 Department of Cardiology, Bishan Hospital, Chongqing University of Chinese Medicine, Chongqing, China 2 Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, ...
"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...